Genetic Polymorphisms in GST Genes and Survival of Colorectal Cancer Patients Treated with Chemotherapy

• Parkin DM , BrayF, FerlayJ, PisaniP: Global cancer statistics, 2002.CA Cancer J. Clin.55(2) , 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Watters JW , McLeodHL: Recent advances in the pharmacogenetics of cancer chemotherapy.Curr. Opin. Mol. Ther.4(6) , 565–571 (2002).
   PubMedGoogle Scholar
• Hayes DF , TrockB, HarrisAL: Assessing the clinical impact of prognostic factors: when is ‘statistically significant‘ clinically useful?Breast Cancer Res. Treat.52(1–3) , 305–319 (1998).
   PubMed Web of Science ®Google Scholar
• Jakobsen A , NielsenJN, GyldenkerneN, LindebergJ: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.J. Clin. Oncol.23(7) , 1365–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Lecomte T , FerrazJM, ZinzindohoueF et al.: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.Clin. Cancer Res.10(17) , 5880–5888 (2004).
   PubMed Web of Science ®Google Scholar
• Raymond E , FaivreS, ChaneyS, WoynarowskiJ, CvitkovicE: Cellular and molecular pharmacology of oxaliplatin.Mol. Cancer Ther.1(3) , 227–235 (2002).
   PubMed Web of Science ®Google Scholar
• Andre T , LouvetC, RaymondE, TournigandC, de Gramont A: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol.9(11) , 1251–1253 (1998).
   PubMed Web of Science ®Google Scholar
• Grothey A , GoldbergRM: A review of oxaliplatin and its clinical use in colorectal cancer.Expert Opin. Pharmacother.5(10) , 2159–2170 (2004).
   PubMed Web of Science ®Google Scholar
• Raymond E , FaivreS, WoynarowskiJM, ChaneySG: Oxaliplatin: mechanism of action and antineoplastic activity.Semin. Oncol.25(2 Suppl. 5) , 4–12 (1998).
   PubMed Web of Science ®Google Scholar
• Kweekel DM , GelderblomH, GuchelaarHJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.Cancer Treat. Rev.31(2) , 90–105 (2005).
   PubMed Web of Science ®Google Scholar
• Adler V , YinZ, FuchsSY et al.: Regulation of JNK signaling by GSTp.EMBO J.18(5) , 1321–1334 (1999).
   PubMed Web of Science ®Google Scholar
• Watson MA , StewartRK, SmithGB, MasseyTE, BellDA: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.Carcinogenesis19(2) , 275–280 (1998).
   PubMed Web of Science ®Google Scholar
• Hayes JD , StrangeRC: Glutathione S-transferase polymorphisms and their biological consequences.Pharmacology61(3) , 154–166 (2000).
   PubMed Web of Science ®Google Scholar
• Ali-Osman F , AkandeO, AntounG, MaoJX, BuolamwiniJ: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π gene variants. Evidence for differential catalytic activity of the encoded proteins.J. Biol. Chem.272(15) , 10004–10012 (1997).
   PubMed Web of Science ®Google Scholar
• Cotton SC , SharpL, LittleJ, BrocktonN: Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review.Am. J. Epidemiol.151(1) , 7–32 (2000).
   PubMed Web of Science ®Google Scholar
• Sprenger R , SchlagenhauferR, KerbR et al.: Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype–phenotype correlation.Pharmacogenetics10(6) , 557–565 (2000).
   PubMedGoogle Scholar
• Seidegard J , DePierreJW, PeroRW: Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s).Carcinogenesis6 , 1211–1216 (1985).
   PubMed Web of Science ®Google Scholar
• Miller SA , DykesDD, PoleskyHF: A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic Acids Res.16(3) , 1215 (1988).
   PubMed Web of Science ®Google Scholar
• Neuhaus T , GeisenG, BoltHM et al.: Reliability of non-invasively acquired human genomic DNA as a substrate for real-time PCR-assisted analysis of genetic polymorphisms.Arch. Toxicol.78(7) , 390–396 (2004).
   PubMed Web of Science ®Google Scholar
• Hirvonen A , SaarikoskiST, LinnainmaaK et al.: Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.J. Natl. Cancer Inst.88(24) , 1853–1856 (1996).
   PubMedGoogle Scholar
• Timofeeva M , JagerB, RosenbergerA et al.: A multiplex real-time PCR method for detection of GSTM1 and GSTT1 copy numbers.Clin. Biochem.42(6) , 500–509 (2009).
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J , ParkDJ, ZhangW et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.Br. J. Cancer91(2) , 344–354 (2004).
   PubMed Web of Science ®Google Scholar
• Townsend DM , TewKD: The role of glutathione-S-transferase in anti-cancer drug resistance.Oncogene22(47) , 7369–7375 (2003).
   PubMed Web of Science ®Google Scholar
• Csejtei A , TiboldA, VargaZ et al.: GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer.Anticancer Res.28(3B) , 1917–1922 (2008).
   PubMed Web of Science ®Google Scholar
• Le Morvan V , SmithD, LaurandA et al.: Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.Pharmacogenomics8(12) , 1693–1703 (2007).
   PubMed Web of Science ®Google Scholar
• Kweekel DM , GelderblomH, AntoniniNF et al.: Glutathione-S-transferase π (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.Eur. J. Cancer45(4) , 572–578 (2009).
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J , ParkDJ, ZhangW et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.J. Natl. Cancer Inst.94(12) , 936–942 (2002).
   PubMedGoogle Scholar
• Funke S , BrennerH, Chang-ClaudeJ: Pharmacogenetics in colorectal cancer: a systematic review.Pharmacogenomics9(8) , 1079–1099 (2008).
   PubMed Web of Science ®Google Scholar

▪ Website

• NCBI SNP homepage www.ncbi.nlm.nih.gov/sites/entrez?db=snp
   Google Scholar